What went well
- Established a $100 million at-the-market (ATM) equity facility on November 28, 2025 with B. Riley Securities and Craig-Hallum Capital Group, adding significant funding flexibility.
- Locked in a November 22, 2025 data cutoff for updated Actuate-1801 mPDAC results, later presented at the ASCO Gastrointestinal Cancers Symposium in January 2026, that continued to show a statistically significant overall-survival benefit for elraglusib plus GnP.
- Narrowed fourth-quarter net loss to $4.6 million from $6.4 million a year earlier, with research and development expense of $2.1 million and general and administrative expense of $2.6 million both down year over year.
- Ended 2025 with $13.2 million in cash and cash equivalents and $7.9 million of working capital.
What went wrong
- Substantial doubt about the company's ability to continue as a going concern remained; the accumulated deficit reached $154.6 million at year-end and cash was projected to fund operations only into July 2026 without additional capital.
- Actuate generated no product revenue and remained a single-asset (elraglusib) clinical-stage business dependent on the capital markets.
- The company drew nothing on the new ATM facility in 2025, and early-2026 ATM sales were priced at roughly $2.68 per share, well below the $7.00 September 2025 offering price, reflecting a sharply lower share price.
Guidance Changes
| Metric | Period | Current guidance |
|---|---|---|
| Cash runway | As of December 31, 2025 | $13.2M in cash; management estimated existing cash would not fund operations beyond July 2026 without raising additional capital |
| Updated Actuate-1801 mPDAC data | January 2026 | Updated overall-survival results (November 22, 2025 cutoff) to be presented at the ASCO GI symposium |
| ATM facility capacity | As of December 31, 2025 | $100M remaining capacity available under the November 2025 ATM program |
Performance Breakdown
| Metric | YoY | Note |
|---|---|---|
| Research & development expense | $2.1M (vs $3.7M) | Lower clinical spend following completion of Phase 2 mPDAC enrollment. |
| General & administrative expense | $2.6M (vs $2.9M) | Lower professional and personnel costs versus the prior-year quarter. |
| Net loss | $4.6M (vs $6.4M) | Lower R&D and G&A spend. |
| Diluted net loss per share | $(0.18) | Loss per share on 23.5M weighted-average shares outstanding. |
| Cash & cash equivalents | $13.2M | $13.2M at December 31, 2025; accumulated deficit of $154.6M. |
Earnings Call Themes & Trends
| Topic | Previous mention | Current period | Trend |
|---|---|---|---|
| Funding capacity | $16.9M cash after September offering | $100M ATM facility established; $13.2M cash at year-end | Up |
| mPDAC data | May 2025 topline | Updated OS data (Nov 22 cutoff) queued for ASCO GI January 2026 | Up |
| Going concern | Doubt persists | Runway into July 2026; accumulated deficit $154.6M | Down |
More on Actuate Therapeutics, Inc.
See how Top Bucket AI works for your firm
Request DemoTop Bucket AI Research
Stay ahead of private markets
Research and market intelligence for private-markets professionals.
✓
You're subscribed.
Thanks for signing up.